Released : May 21, 2018 07:00 RNS Number : 6263O MaxCyte, Inc. 21 May 2018 MaxCyte, Inc. ("MaxCyte" or the "Company") MaxCyte Reports Preclinical Results at ASGCT Annual Meeting Showing Correction of Sickle Cell Disease Mutation in Hematopoietic Stem Cells - Data demonstrate the
Released : April 30, 2018 07:00 RNS Number : 4680M MaxCyte, Inc. 30 April 2018 MaxCyte, Inc. ("MaxCyte" or the "Company") Notice of AGM and 2017 Annual Report and Accounts Gaithersburg, Maryland - 30 April 2018: MaxCyte (LSE: MXCT, MXCR), the global cell-based medicines and life
Released : April 25, 2018 07:00 RNS Number : 9826L MaxCyte, Inc. 25 April 2018 MaxCyte, Inc. ("MaxCyte" or the "Company") MaxCyte Appoints Dr Claudio Dansky Ullmann as Chief Medical Officer · Dr Dansky Ullmann joins the Company as MaxCyte prepares for clinical testing of its first
Released : April 04, 2018 07:00 RNS Number : 7161J MaxCyte, Inc. 04 April 2018 MaxCyte, Inc. ("MaxCyte" or the "Company") MaxCyte Reports Final Results for Year Ended 31 December 2017 Gaithersburg, Maryland - 04 April 2018: MaxCyte (LSE: MXCT, MXCR), the global cell-based medicines
Released : March 15, 2018 07:00 RNS Number : 7489H MaxCyte, Inc. 15 March 2018 MaxCyte, Inc. ("MaxCyte" or the "Company") Notice of Full Year Results Gaithersburg, Maryland - 15 March 2018: MaxCyte (LSE: MXCT, MXCR), a global cell-based medicines and life sciences company , will be
Gaithersburg, Maryland – 12 March 2018: MaxCyte announced today that Debra K. Bowes, Executive Vice President, Business and Strategic Development , will present at two key life sciences conferences this month: the 12 th Annual International Partnering Conference: BIO Europe Spring on March 14
Released : February 28, 2018 17:00 RNS Number : 3007G MaxCyte, Inc. 28 February 2018 MaxCyte, Inc. ("MaxCyte" or the "Company") Director Dealings Maryland, USA , 28 February 2018 - MaxCyte (LSE: MXCT, MXCR) the global cell-based medicines and technology company, announces that J.
Released : February 15, 2018 07:00 RNS Number : 9370E MaxCyte, Inc. 15 February 2018 MaxCyte, Inc. ("MaxCyte" or the "Company") Grant of Options Maryland, USA , 15 February 2018 - MaxCyte (LSE: MXCT, MXCR) the global cell-based medicines and technology company, announces that it
Released : February 13, 2018 07:00 RNS Number : 6464E MaxCyte, Inc. 13 February 2018 MaxCyte, Inc. ("MaxCyte" or the "Company") Dr Richard Douglas Joins MaxCyte Board Dr Douglas previously served as Senior Vice President of Corporate Development at Genzyme Gaithersburg, Maryland - 13
Released : February 01, 2018 16:06 RNS Number : 6932D MaxCyte, Inc. 01 February 2018 SCHEDULE 6 AIM BLOCK ADMISSION SIX MONTHLY RETURN Please ensure the entries on this return are typed a. Name of company MaxCyte, Inc. b. Name of scheme(s) MaxCyte Long Term Incentive Plan c.
